RECIPROCAL SERUM/PLASMA EXCHANGE FOR TREATMENT OF CANCER
Background: Caners continues to be a major health care issue. For example, pancreatic cancer claims about ~30,000 lives annually. The immune systems response in this disease remains poorly understood. We and others have found that IgE and IgG specific for selective proteins can provide protection in infection (HIV) and malignant (ovarian cancer) disease. The rationale behind reciprocal serum/plasma exchange is that serum/plasma from one patient makes anti-cancer antibodies which may not able to destroy the patient’s own cancer but are developed and different enough to recognize and kill a similar (or in some cases different) cancer in a different patient.
Cancer market:
Ø Prevalence increases with age
Ø Second most common cause of death in US (1st is heart disease)
Ø Chemotherapy is often not effective in certain cancers
Ø Prostate and breast cancer are the leading causes of cancer death men and women, respectively
Ø Mortality rate is >500,00 year
Ø Costs an estimated $228 billion a year (ACS data)
Ø Direct medical costs (total of all health expenditures): $ 93 billion
Ø Indirect morbidity costs (cost of lost productivity due to illness): $ 19 billion
Ø Indirect mortality costs (cost of lost productivity due to premature death): $116 billion
Clinical Data: IgE which is found in trace amounts in human serum is nonetheless extremely potent to induce antibody dependent cell mediated cytotoxicity (ADCC) against cancer antigen expressing cells and thus can provide a potent anti-tumor response. We have recently shown that in pancreatic cancer (1) IgE and its low affinity receptor CD23 are selectively upregulated vs other immunoglobulin isotypes IgG, IgM, IgA) (2) IgE and IgG recognize a 50kd protein in commercially available pancreatic cancer cell lysates (PANC-1, MiaPaca, HPAC) and (3) IgE can kill pancreatic cancer cells by ADCC. These responses are patient specific and show a uniquely potent immune response by IgE. As such reciprocal serum/plasma exchange can treat a number of different cancers by providing a boosted immune system to the cancer patient.
IP: Reciprocal serum/plasma exchange for the treatment of cancer – Dr Bluth, Patent filed/pending, foming new entity
References:
1. Fu S, Pierre J, Smith-Norowitz TA, Hagler M, Bowne W, Pincus MR, Mueller CM, Zenilman ME, Bluth MH. IgE antibodies from pancreatic cancer patients mediate antibody-dependent cell meditate cytotoxicity (ADCC) against pancreatic cancer cells. Clinical and Experimental Immunology 2008;153:401-409
Background: Caners continues to be a major health care issue. For example, pancreatic cancer claims about ~30,000 lives annually. The immune systems response in this disease remains poorly understood. We and others have found that IgE and IgG specific for selective proteins can provide protection in infection (HIV) and malignant (ovarian cancer) disease. The rationale behind reciprocal serum/plasma exchange is that serum/plasma from one patient makes anti-cancer antibodies which may not able to destroy the patient’s own cancer but are developed and different enough to recognize and kill a similar (or in some cases different) cancer in a different patient.
Cancer market:
Ø Prevalence increases with age
Ø Second most common cause of death in US (1st is heart disease)
Ø Chemotherapy is often not effective in certain cancers
Ø Prostate and breast cancer are the leading causes of cancer death men and women, respectively
Ø Mortality rate is >500,00 year
Ø Costs an estimated $228 billion a year (ACS data)
Ø Direct medical costs (total of all health expenditures): $ 93 billion
Ø Indirect morbidity costs (cost of lost productivity due to illness): $ 19 billion
Ø Indirect mortality costs (cost of lost productivity due to premature death): $116 billion
Clinical Data: IgE which is found in trace amounts in human serum is nonetheless extremely potent to induce antibody dependent cell mediated cytotoxicity (ADCC) against cancer antigen expressing cells and thus can provide a potent anti-tumor response. We have recently shown that in pancreatic cancer (1) IgE and its low affinity receptor CD23 are selectively upregulated vs other immunoglobulin isotypes IgG, IgM, IgA) (2) IgE and IgG recognize a 50kd protein in commercially available pancreatic cancer cell lysates (PANC-1, MiaPaca, HPAC) and (3) IgE can kill pancreatic cancer cells by ADCC. These responses are patient specific and show a uniquely potent immune response by IgE. As such reciprocal serum/plasma exchange can treat a number of different cancers by providing a boosted immune system to the cancer patient.
IP: Reciprocal serum/plasma exchange for the treatment of cancer – Dr Bluth, Patent filed/pending, foming new entity
References:
1. Fu S, Pierre J, Smith-Norowitz TA, Hagler M, Bowne W, Pincus MR, Mueller CM, Zenilman ME, Bluth MH. IgE antibodies from pancreatic cancer patients mediate antibody-dependent cell meditate cytotoxicity (ADCC) against pancreatic cancer cells. Clinical and Experimental Immunology 2008;153:401-409